LEWIS AND CLARK PHARMACEUTICALS INC has a total of 26 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2013. It filed its patents most often in United States, Australia and Brazil. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are ALCASYNN PHARMACEUTICALS GMBH, NEUROSCIENZE PHARMANESS S C A R L and BIOTIE THERAPIES GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | Australia | 2 | |
#3 | Brazil | 2 | |
#4 | China | 2 | |
#5 | EAPO (Eurasian Patent Organization) | 2 | |
#6 | EPO (European Patent Office) | 2 | |
#7 | Israel | 2 | |
#8 | Mexico | 2 | |
#9 | WIPO (World Intellectual Property Organization) | 2 | |
#10 | Canada | 1 | |
#11 | India | 1 | |
#12 | Republic of Korea | 1 | |
#13 | New Zealand | 1 | |
#14 | Singapore | 1 | |
#15 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Sugars | |
#3 | Heterocyclic compounds | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Beauglehole Anthony | 20 |
#2 | Wang Guoquan | 20 |
#3 | Thompson Robert | 16 |
#4 | Anthony Beauglehole | 5 |
#5 | Guoquan Wang | 5 |
#6 | Robert Thompson | 5 |
#7 | Thompson Robert D | 4 |
Publication | Filing date | Title |
---|---|---|
AU2016246068A1 | Xanthine-substituted alkynyl carbamates/reverse carbamates as A2b antagonists | |
US2016376302A1 | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists | |
MX2015001370A | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists. |